Newsletter Subject

The Nascent Industry Taking On an $8.5 Trillion Juggernaut!

From

profittrends.com

Email Address

profittrends@mb.profittrends.com

Sent On

Tue, Sep 15, 2020 07:54 PM

Email Preheader Text

For years, psychedelic mushrooms have been demonized. But today, those attitudes are changing. SPONS

For years, psychedelic mushrooms have been demonized. But today, those attitudes are changing. [Profit Trends]( SPONSORED [Looming Crisis Could Hit Americans on September 16, 2020]( [Scary Chart]( chart shows that Washington will be virtually helpless when the next crisis hits. That's why it could do something drastic on September 16, 2020... something that could bring this market to a sudden stop. [Details Here!]( [MARKET TRENDS]( The Nascent Industry Taking On an $8.5 Trillion Juggernaut Matthew Carr | Chief Trends Strategist | The Oxford Club [Matthew Carr] The global healthcare industry is a juggernaut with a capital "J." And I'm not talking about the gem-empowered supervillain who routinely squares off against Deadpool, Hulk, Spider-Man, the X-Men and pretty much everyone in the Marvel Universe who gets in his way. But the healthcare industry is nonetheless undeniably enormous... and only getting more so. In 2018, the industry was worth $8.45 trillion. By 2022, thanks to the [graying of America]( and the rapidly aging world population, global healthcare spending is projected to top $10 trillion. In most developed countries, it accounts for roughly 10% of gross domestic product (GDP). In countries where healthcare is more expensive, like the U.S., it's closer to 20% of GDP. Healthcare is one of the largest and fastest-growing industries in the world. And that's why investors need to sit up and pay attention, because it is about to get disrupted. The Other 21st-Century Solution Over the years, I've discussed how new technologies are going to create massive opportunities in healthcare. These disrupters are creating waves as we speak. For example, the Internet of Things is poised to reduce healthcare costs and inefficiencies by as much as $100 billion per year. Precision medicine is on the path to topping $119 billion as we enter a new era of personalized treatment. Telemedicine is skyrocketing. Artificial intelligence and surgical robots are here. These are sci-fi, 21st-century solutions to healthcare. But the technological advancements over the last few decades have allowed another set of disrupters to emerge from the shadows. These are things humanity has turned to for millennia, though we're only now beginning to scratch the surface of how and why they work. And what potential they ultimately have. Take cannabis for instance... Five thousand years ago, the fabled Chinese emperor Shen Nung prescribed cannabis for a laundry list of ailments. In ancient India, it was seen as a gift from the gods. And in Materia Medica, published in A.D. 70, the Roman physician Pedanius Dioscorides recommended cannabis for earaches and diminished libido. We know it has a wide range of [medical uses](. Doctors prescribe it to treat chronic pain, sleep disorders, eating disorders, PTSD, anxiety and depression. You name it - marijuana has the potential to help. And up until the 1930s and the rise of "[Reefer Madness]( cannabis was a valued medicine. But it wasn't until the 1990s that scientists discovered humans had an endocannabinoid system. There is an entire system throughout our bodies hardwired to react to cannabis, which impacts our appetite, memory, energy, stress responses, immune functions, sleep and more. In the couple of decades since, attitudes toward cannabis have started to shift. Though only very recently has cannabis moved from being seen as a dangerous drug to being recognized as a potential miracle worker. In turn, countries have started legalizing marijuana, as we're witnessing here in the U.S. And we know on [election night]( the number of states greenlighting cannabis use will continue to grow. But there's another nascent pharmaceutical development I believe investors must open their eyes to. Just as they did with cannabis. SPONSORED [Virginia Stock-Picking Millionaire Breaks No. 1 Rule of Investing...]( He bought Apple 22 years ago... Amazon 13 years ago... and Netflix more than a decade ago. Now one of the world's greatest stock pickers is breaking the No. 1 rule of investing... and targeting a $3 stock that trades under a secret name. [See him explain his crazy approach live on stage here.]( The $100 Billion Psychedelic Breakthrough Mushrooms have been consumed by humans for eons. Thousands of years ago, the Divine Farmer's Materia Medica - one of the foundational texts of Chinese wellness practices - described the health benefits of fungi. But beyond button, chanterelle, linghzi, porcini and portobello, we all know there's a "magic mushroom" variety as well. The psychedelic kind. These are so ingrained in our collective psyche that I bet we all picture the same image when hearing the words "magic mushrooms" - white stalks with red caps and white spots. The infamous fly agaric, the pedestal for fairies and pixies, is pictured in everything from Alice in Wonderland to The Smurfs. The Celtic druids referred to these mushrooms as the "flesh of the gods" because of their mind-boosting attributes. The Aztecs had their own "flesh of the gods," the teonanácatl mushroom. And it's believed humans have been chomping on hallucinogenic mushrooms since roughly 9000 B.C. But they offer more than just "trips." They are actually a living medicine. Unfortunately, like cannabis, mushrooms were demonized. But like the opinions on cannabis, those attitudes are changing, with states leading the charge on decriminalization, as we rediscover that these mushrooms - and their active compound psilocybin - could be pivotal in treating various mental illnesses. In October 2018, the U.S. Food and Drug Administration gave the thumbs-up to research the use of mushrooms to combat treatment-resistant depression. And it fast-tracked a second psilocybin treatment for depression a year later. In September 2019, Johns Hopkins University unveiled its Center for Psychedelic and Consciousness Research. This will explore using psilocybin to treat opioid addiction, alcohol and nicotine dependency, Lyme disease, PTSD, and more. Last year, Denver, Colorado, and Oakland, California, decriminalized psychedelic mushrooms. This year, Santa Cruz, California, followed suit. And in November, Oregon and Washington, D.C., will vote on measures to do the same. It's now estimated the global market for psilocybin and psychedelic medicine will top $100 billion. And our long history of consuming has real monetary benefits. Typically, it takes a decade and $2.6 billion to develop a prescription drug. But treatments using psilocybin and mushrooms - because of the decades and decades of consumption already documented - could take a lot less time. And right now, there are more than a dozen psychedelic clinical trials underway in the U.S. We are on the cusp of a nascent industry that will tackle some of the most devastating diseases and mental health issues on the planet. And it's disrupting one of the largest and fastest-growing industries on Earth - an $8.5 trillion juggernaut. And Silicon Valley legends, billionaire financiers, huge hedge funds, Wall Street and Big Pharma are all taking notice. That means investors must do the same. Here's to high returns, Matthew P.S. Later this week, I'll be launching a special video presentation all about the psychedelic medicine breakthrough and the massive investment opportunities it offers with this new era of "living medicine." Stay tuned... [Leave a Comment]( MORE FROM PROFIT TRENDS [The Sports Betting Opportunity Investors Can't Ignore]( [How to Manage the Most Difficult Part of Investing]( [Pollution in Oceans Is Leading to Plastic in Your Body]( [Facebook]( [Facebook]( [Twitter]( [Twitter]( [Email Share](mailto:?subject=A%20great%20piece%20from%20Profit%20Trends...&body=From%20Profit%20Trends:%0D%0A%0D%0AFor%20years,%20psychedelic%20mushrooms%20have%20been%20demonized.%20But%20today,%20those%20attitudes%20are%20changing.%0D%0A%0D [Email Share](mailto:?subject=A%20great%20piece%20from%20Profit%20Trends...&body=From%20Profit%20Trends:%0D%0A%0D%0AFor%20years,%20psychedelic%20mushrooms%20have%20been%20demonized.%20But%20today,%20those%20attitudes%20are%20changing.%0D%0A%0D SPONSORED [BIG Real Estate Profits... NONE of the Hassle]( [Businessman Woman Hand Holding Model Home]( Collect real estate income with just $30 to start! No flipping houses, no chasing down rent checks - none of that! It's the easiest way to start collecting real estate income without having to buy a property yourself. Forbes reports that this special type of real estate investment has "a long history of outperforming direct real estate investing." [Click here to discover a BETTER way to get rich from real estate.]( [The Oxford Club] You are receiving this email because you subscribed to Profit Trends. Profit Trends is published by The Oxford Club. Questions? Check out our [FAQs](. Trying to reach us? [Contact us here.]( Please do not reply to this email as it goes to an unmonitored inbox. [Privacy Policy]( | [Whitelist Profit Trends]( | [Unsubscribe]( © 2020 The Oxford Club, LLC All Rights Reserved The Oxford Club | [105 West Monument Street](#) | [Baltimore, MD 21201](#) North America: [1.800.589.3430](#) | International: [+1.443.353.4334](#) | Fax: [1.410.329.1923](#) [Oxfordclub.com]( The Oxford Club is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. Members should be aware that although our track record is highly rated by an independent analysis and has been legally reviewed, investment markets have inherent risks and there can be no guarantee of future profits. The stated returns may also include option trades. We expressly forbid our writers from having a financial interest in their own securities recommendations to readers. All of our employees and agents must wait 24 hours after online publication or 72 hours after the mailing of printed-only publications prior to following an initial recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, 105 W. Monument Street, Baltimore MD 21201.

Marketing emails from profittrends.com

View More
Sent On

26/05/2022

Sent On

24/05/2022

Sent On

21/05/2022

Sent On

21/05/2022

Sent On

20/05/2022

Sent On

19/05/2022

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.